Results of sclerotherapy in 100 patients comparison of the outcome between schistosomiasis and hepatitis B.
One hundred patients received sclerotherapy for acutely bleeding esophageal varices. Seventy per cent of these patients had chronic liver disease due to schistosomiasis or hepatitis B. The remaining 30% had chronic liver disease of other etiology, including alcohol in 2%. Our study shows a favorable outcome of sclerotherapy in the schistosomal group during a mean follow-up period of 39 months. Esophageal varices were completely sclerosed in 53.3% of schistosoma patients, in 37.5% of hepatitis B, and in 42.3% of other groups. The rebleeding rate was 11.1% in schistosomiasis, 43.8% in hepatitis B and 33.3% in other groups. The overall mortality rate was 4.4% in the schistosomal group, 50.0% in the hepatitis B, and 40% in other groups. Rebleeding from gastric varices occurred in 17 patients, 13 of whom died, including 11 who were operated on for bleeding gastric varices and died following surgery.